Data gathered: November 27
AI Stock Analysis - Arrowhead Pharmaceuticals (ARWR)
Analysis generated November 26, 2024. Powered by Chat GPT.
Arrowhead Pharmaceuticals, a biopharmaceutical company, is involved in the development of RNA interference (RNAi) medicines. The company focuses on therapeutics that cure intractable diseases by silencing the genes that cause them. With a strong pipeline of drug candidates targeting diseases such as hepatitis B, cystic fibrosis, and cardiovascular diseases, Arrowhead leverages its proprietary technology to tackle conditions with unmet medical needs.
Stock Alerts - Arrowhead Pharmaceuticals (ARWR)
 |
Arrowhead Pharmaceuticals | November 27 Price is up by 7.4% in the last 24h. |
|
Arrowhead Pharmaceuticals | November 26 Price is up by 25.2% in the last 24h. |
|
Arrowhead Pharmaceuticals | November 25 Price is up by 5.6% in the last 24h. |
|
Arrowhead Pharmaceuticals | November 16 Insider Alert: Lu Hongbo is buying shares |
Alternative Data for Arrowhead Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 13 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 35 | Sign up | Sign up | Sign up |
| Patents | 93 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 65 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,729 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,620 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | 547 | Sign up | Sign up | Sign up |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
| Price | $26.15 |
| Target Price | Sign up |
| Volume | 5,820,000 |
| Market Cap | $2.62B |
| Year Range | $17.7 - $29.54 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
 |
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of “Moderate Buy” from AnalystsNovember 27 - ETF Daily News |
 |
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call TranscriptNovember 26 - SeekingAlpha |
 |
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End ResultsNovember 26 - Yahoo |
Arrowhead Pharmaceuticals : Reports 2024 Fiscal Year End Results Form 8 KNovember 26 - Finnhub |
|
 |
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical ProgramsNovember 25 - Yahoo |
|
18,705 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Purchased by B. Metzler seel. Sohn & Co. Holding AGNovember 25 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 31M | -32M | -171M | -157M | -1.370 |
| Q2 '24 | 0 | 24M | -24M | -171M | -171M | -1.380 |
| Q1 '24 | 0 | 25M | -33M | -125M | -114M | -1.020 |
| Q4 '23 | 3.6M | 28M | -30M | -133M | -127M | -1.240 |
| Q3 '23 | 11M | 28M | -18M | -110M | -99M | -1.020 |
Insider Transactions View All
| Oliver Tracie filed to sell 127,107 shares at $25.3. July 3 '24 |
| Vakiener Victoria filed to sell 30,205 shares at $23.3. May 6 '24 |
| Lu Hongbo filed to buy 36,080 shares at $22. November 15 '24 |
| Lu Hongbo filed to buy 35,080 shares at $27.3. November 15 '24 |
| Hamilton James C filed to sell 204,851 shares at $28. April 3 '24 |
Similar companies
Read more about Arrowhead Pharmaceuticals (ARWR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arrowhead Pharmaceuticals?
The Market Cap of Arrowhead Pharmaceuticals is $2.62B.
What is the current stock price of Arrowhead Pharmaceuticals?
Currently, the price of one share of Arrowhead Pharmaceuticals stock is $26.15.
How can I analyze the ARWR stock price chart for investment decisions?
The ARWR stock price chart above provides a comprehensive visual representation of Arrowhead Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arrowhead Pharmaceuticals shares. Our platform offers an up-to-date ARWR stock price chart, along with technical data analysis and alternative data insights.
Does ARWR offer dividends to its shareholders?
As of our latest update, Arrowhead Pharmaceuticals (ARWR) does not offer dividends to its shareholders. Investors interested in Arrowhead Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arrowhead Pharmaceuticals?
Some of the similar stocks of Arrowhead Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.